638 related articles for article (PubMed ID: 18221983)
1. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
[TBL] [Abstract][Full Text] [Related]
4. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
Cansu DU; Kalifoglu T; Korkmaz C
J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
6. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
8. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.
Benucci M; Manfredi M; Mecocci L
J Clin Rheumatol; 2008 Aug; 14(4):245-6. PubMed ID: 18766129
[No Abstract] [Full Text] [Related]
9. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
Ang HT; Helfgott S
J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
11. Chronic viral hepatitis and TNF-alpha blockade.
Raftery G; Griffiths B; Kay L; Kane D
Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
[No Abstract] [Full Text] [Related]
12. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
13. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
15. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
16. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
17. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
Parke FA; Reveille JD
Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
Jit M; Henderson B; Stevens M; Seymour RM
Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
[TBL] [Abstract][Full Text] [Related]
20. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
Gottlieb GS; Lesser CF; Holmes KK; Wald A
Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]